The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study

Lawrence Engmann, Andrea DiLuigi, David Schmidt, +3

Fertility and Sterility

InfertilityHormonal ContraceptiveFertilityFemale InfertilityReproductive Health +13

Meiotic Arrest in Human Oocytes Is Maintained by a Gs Signaling Pathway1

Andrea DiLuigi, Vanessa N. Weitzman, Margaret C. Pace, +3

Biology of Reproduction

OocyteMeiotic ArrestGeneticsReproductive BiologyEpigenetics +16

Prevention of recurrent adnexal torsion

Vanessa N. Weitzman, Andrea DiLuigi, Donald Maier, +1

Fertility and Sterility

Recurrent Adnexal TorsionClinical DisordersDegenerative Disease

Impact of trophectoderm biopsy on obstetric and perinatal outcomes following frozen–thawed embryo transfer cycles

Reeva Makhijani, Chantal Bartels, Prachi N. Godiwala, +6

Human Reproduction

The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study

Lawrence Engmann, Andrea DiLuigi, David Schmidt, +3

Fertility and Sterility

Vitro Fertilization TreatmentFertilityReproductive HealthGynecologyProspective Randomized Study +7

Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting

Andrea DiLuigi, Lawrence Engmann, David Schmidt, +3

Fertility and Sterility

InfertilityUrologyFertilityReproductive HealthGynecology +12

A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders

Andrea DiLuigi, Lawrence Engmann, David Schmidt, +2

Fertility and Sterility

Clinical TrialsTreatment OptionExperimental TherapeuticPredicted Poor RespondersPharmacotherapy +2

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes

Vanessa N. Weitzman, Lawrence Engmann, Andrea DiLuigi, +3

Fertility and Sterility

Vitro Fertilization OutcomesInfertilityHormonal ContraceptiveFertilityGynecology +10

Selection of first in vitro fertilization cycle stimulation protocol for good prognosis patients: gonadotropin releasing hormone antagonist versus agonist protocols.

E.B. Johnston-MacAnanny, Andrea DiLuigi, L.L. Engmann, +3

PubMed

Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome – a prospective randomized double-blind clinical trial

L.L. Engmann, B.-S.L. Maslow, Leah A. Kaye, +6

Journal of Ovarian Research